Changes in platelet size induced by treatment in patients with Myeloproliferative Neoplasms. Cytoskeletal study during platelet production.

CELLUCCI AS ; LEV PR; YAÑUK D; GOETTE NP; GLEMBOTSKY AC; DE LUCA G; LIRA MC; BARONI PIETO MC; HELLER PG; BARONI PIETTO MC FLORES G6, HELLER PG1,2, GOETTE NP1, MARTA RF1,2.

Congreso; Congress of the International Society on Thrombosis and Haemostasis (ISTH); 2023

Hydroxyurea (HU), α-Interferon (α-IFN), anagrelide (ANA) and ruxolitinib (Ruxo) are used in MPN treatment, conditions associated to thrombosis. Considering that large platelets could be related to thrombotic events, Maximum Platelet Diameter (MPD) was evaluated in blood smears from 76 MPN patients (table1). Increased MPD was found in patients treated with αIFN, ANA and Ruxo compared to controls (n=37) and HU (p